Abstract:
Background. Although there are a number of studies comparing the currently recommended preferred and alternative first-line
(1L) antiretroviral therapy (ART) regimens on clinical outcomes, there are limited data examining the impact of 1L regimen choice
and duration of virologic failure (VF) on accumulation of drug resistance mutations (DRM). The patterns of DRM from patients
failing zidovudine (AZT)-containing versus tenofovir (TDF)-containing ART were assessed to evaluate the predicted susceptibility
to second-line (2L) nucleoside reverse-transcriptase inhibitor (NRTI) backbone options in the context of an ongoing programmatic
setting that uses viral load (VL) monitoring.
Methods. Paired samples from Nigerian ART patients who experienced VF and switched to 2L ART were retrospectively identified.
For each sample, the human immunodeficiency virus (HIV)-1 polymerase gene was sequenced at 2 time points, and DRM was
analyzed using Stanford University’s HIVdb program.
Results. Sequences were generated for 191 patients. At time of 2L switch, 28.2% of patients on AZT-containing regimens developed
resistance to TDF, whereas only 6.8% of patients on TDF-containing 1L had mutations compromising susceptibility to AZT.
In a stratified evaluation, patients with 0–6 months between tested VL samples had no difference in proportion compromised to 2L,
whereas those with >6 months between samples had a statistically significant difference in proportion with compromised 2L NRTI.
In multivariate analyses, patients on 1L AZT had 9.90 times higher odds of having a compromised 2L NRTI option than patients on
1L TDF.
Conclusions. In the context of constrained resources, where VL monitoring is limited, we present further evidence to support
use of TDF as the preferred 1L NRTI because it allows for preservation of the recommended 2L NRTI option.
